Daily Cosmetic Research Analysis
Three clinically oriented studies stand out today. A rigorous meta-analysis clarifies first-line therapy for autoimmune hepatitis, balancing efficacy and adverse events including cosmetic effects. An ophthalmology meta-analysis finds chlorhexidine comparable to povidone-iodine for intravitreal injection antisepsis with better tolerability, and a retrospective cohort shows quantifiable skeletal and psychosocial benefits from facial feminization surgery in East Asian women.
Summary
Three clinically oriented studies stand out today. A rigorous meta-analysis clarifies first-line therapy for autoimmune hepatitis, balancing efficacy and adverse events including cosmetic effects. An ophthalmology meta-analysis finds chlorhexidine comparable to povidone-iodine for intravitreal injection antisepsis with better tolerability, and a retrospective cohort shows quantifiable skeletal and psychosocial benefits from facial feminization surgery in East Asian women.
Research Themes
- Evidence synthesis guiding first-line therapy choices
- Procedure protocol optimization balancing efficacy and tolerability
- Objective and patient-reported outcomes in gender-affirming facial surgery
Selected Articles
1. What is the optimal first-line treatment of autoimmune hepatitis? A systematic review with meta-analysis of randomised trials and comparative cohort studies.
This meta-analysis of 7 RCTs and 18 cohort studies shows that prednisone reduces death/transplantation in autoimmune hepatitis, with additional benefit from combining azathioprine. Higher initial steroid doses provide no clear efficacy advantage and increase adverse events. Budesonide offers similar biochemical response to prednisone with fewer cosmetic adverse effects, and mycophenolate is an alternative to azathioprine with fewer serious AEs.
Impact: Synthesizes the highest-quality evidence to refine first-line AIH therapy, directly informing drug choice and dosing while incorporating patient-important outcomes such as cosmetic adverse effects.
Clinical Implications: Use prednisone plus azathioprine as standard first-line where tolerated; avoid high initial steroid doses due to increased AEs without efficacy gain. Consider budesonide when minimizing cosmetic steroid effects is a priority and mycophenolate for azathioprine intolerance.
Key Findings
- Prednisone (± azathioprine) reduced death/transplantation versus no prednisone across several subgroups (overall RR 0.38, 95% CI 0.20–0.74).
- Prednisone plus azathioprine lowered death/transplantation compared with prednisone alone (RR 0.38, 95% CI 0.22–0.65).
- Higher initial prednisone doses did not improve biochemical response (RR 1.07) and increased adverse events (RR 1.73).
- Budesonide achieved similar biochemical response to prednisone (RR 0.99) with fewer cosmetic adverse events (RR 0.46); MMF had similar efficacy to azathioprine with fewer discontinuation-requiring AEs (RR 0.20).
Methodological Strengths
- Included 7 RCTs (majority low risk of bias) and 18 comparative cohorts with random-effects meta-analysis.
- Formal risk-of-bias assessment using Cochrane ROB-2 and ROBINS-1.
Limitations
- Heterogeneity and moderate-to-high risk of bias in several cohort studies, especially for mortality outcomes.
- Total pooled sample size and subgroup-specific data not fully detailed in the abstract.
Future Directions: Head-to-head RCTs of budesonide vs prednisone stratified by disease severity; dose-optimization trials; pragmatic trials comparing azathioprine vs mycophenolate with long-term outcomes and patient-centered (including cosmetic) AEs.
OBJECTIVES: Uncertainty remains about many aspects of first-line treatment of autoimmune hepatitis (AIH). DESIGN: Systemic review with meta-analysis (MA). DATA SOURCES: Bespoke AIH Endnote Library, updated to 30 June 2024. ELIGIBILITY CRITERIA: Randomised controlled trials (RCTs) and comparative cohort studies including adult patients with AIH, reporting death/transplantation, biochemical response (BR) and/or adverse effects (AEs). DATA EXTRACTION AND SYNTHESIS: Data pooled in MA as relative risk (RR) under random effects. Risk of bias (ROB) assessed using Cochrane ROB-2 and ROBINS-1 tools. RESULTS: From seven RCTs (five with low and two with some ROB) and 18 cohort studies (12 moderate ROB, six high for death/transplant), we found lower death/transplantation rates in (a) patients receiving pred+/-aza (vs no pred): overall (RR 0.38 (95% CI 0.20 to 0.74)), in patients without symptoms (0.38 (0.19-0.75)), without cirrhosis (0.30 (0.14-0.65)), and with decompensated cirrhosis (RR 0.38 (0.23-0.61)), and (b) patients receiving pred+aza (vs pred alone) (0.38 (0.22-0.65)). Patients receiving higher (vs lower) initial pred doses had similar BR rates (RR 1.07 (0.92-1.24)) and mortality (0.71 (0.25-2.05)) but more AEs (1.73 (1.17-2.55)). Patients receiving bud (vs pred) had similar BR rates (RR 0.99 (0.71-1.39)), with fewer cosmetic AEs (0.46 (0.34-0.62)). Patients receiving mycophenolate mofetil (MMF) (vs aza) had similar BR rates (RR 1.32 (0.73-2.38)) and fewer AEs requiring drug cessation (0.20 (0.09-0.43)). CONCLUSIONS: Mortality is lower in pred-treated (vs untreated) patients, overall and in several subgroups, and in those receiving pred+aza (vs pred). Higher initial pred doses confer no clear benefit and cause more AEs. Bud (vs pred) achieves similar BR rates, with fewer cosmetic AEs. MMF (vs aza) achieves similar BR rates, with fewer serious AEs.
2. Chlorhexidine Versus Povidone-Iodine for Intravitreal Injection Antisepsis: A Systematic Review and Meta-Analysis.
Across seven comparative studies, chlorhexidine and povidone-iodine yielded similar rates of presumed and culture-confirmed endophthalmitis after intravitreal injections. Visual outcomes were comparable, but chlorhexidine provided better tolerability and lower pain, and was associated with fewer S. epidermidis-positive cultures in endophthalmitis cases.
Impact: Intravitreal injections are performed at massive scale; demonstrating comparable infection prophylaxis with improved patient comfort can shift antisepsis protocols and patient experience.
Clinical Implications: Chlorhexidine is a reasonable alternative to povidone-iodine for pre-injection antisepsis, especially in patients with iodine sensitivity or poor tolerance to PI. Implementation should consider local protocols, CHX concentration, and rare-event surveillance.
Key Findings
- No significant difference between chlorhexidine and povidone-iodine in presumed, culture-positive, or culture-negative postinjection endophthalmitis rates.
- Best-corrected visual acuity outcomes in endophthalmitis cases were comparable between antiseptics.
- Chlorhexidine showed better tolerability and lower pain than povidone-iodine.
- Chlorhexidine was associated with lower odds of S. epidermidis-positive cultures in endophthalmitis cases.
Methodological Strengths
- Systematic multi-database search with predefined inclusion criteria and random-effects meta-analysis.
- Appropriate statistical methods (Mantel–Haenszel for dichotomous, inverse variance for continuous outcomes).
Limitations
- Only seven studies; potential heterogeneity in protocols, antiseptic concentrations, and outcome definitions.
- Rare event rates limit power to detect small differences in endophthalmitis incidence.
Future Directions: Large, pragmatic randomized trials directly comparing PI vs CHX at standardized concentrations, with patient-reported pain, cost, and microbiologic endpoints; implementation studies across high-volume clinics.
PURPOSE: While povidone-iodine (PI) is a commonly used antiseptic solution for postinjection endophthalmitis (PIE) prophylaxis, chlorhexidine (CHX) may be better tolerated by patients. This systematic review and meta-analysis aims to comprehensively compare the efficacy and safety of CHX and PI for PIE prophylaxis. DESIGN: Systematic Review and Meta-Analysis. METHODS: MEDLINE, Embase, and the Cochrane Library were systematically searched for relevant literature from January 2000 to July 2024. Studies that compared CHX with PI for either PIE prophylaxis, functional outcomes, or safety outcomes were included. A random-effects meta-analysis was performed, using the Mantel-Haenszel method for dichotomous outcomes and inverse variance method for continuous outcomes. The primary outcomes were the comparative PIE incidence after CHX versus PI. Secondary outcomes pertained to best-corrected visual acuity (BCVA), patient intolerance, pain, safety endpoints, and specimens cultured. RESULTS: A total of seven studies were included. The incidence of presumed PIE (n CONCLUSIONS: CHX and PI were associated with nonsignificantly different rates of presumed, culture-positive, and culture-negative PIE. Endophthalmitis cases associated with both antiseptic agents had a comparable prognosis with respect to BCVA. However, CHX exhibited a more favorable safety and pain profile compared to PI and was associated with a lower odds of positive S. epidermidis cultures in endophthalmitis cases.
3. Middle and lower-facial feminization surgery in East Asian transgender and cisgender women: Surgical techniques and outcomes.
In a single-center retrospective cohort (34 transgender and 39 cisgender East Asian women), reduction malarplasty and mandibular angle ostectomy significantly reduced mid/lower facial width and mandibular angle. Complications were mainly transient nerve weakness. Transgender women showed greater improvements in FACE-Q appearance and psychosocial scores versus cisgender women.
Impact: Provides quantitative skeletal outcomes and validated patient-reported measures in East Asian patients, informing gender-affirming surgical planning and expectations.
Clinical Implications: Supports reduction malarplasty and mandibular contouring as effective components of facial feminization in East Asian patients; counseling can emphasize significant aesthetic and psychosocial benefits and the typically transient nature of nerve weakness.
Key Findings
- Significant reductions in mid- and lower-facial width and mandibular angle were achieved in all patients (P<.001).
- Primary complications were transient nerve weaknesses.
- Transgender women had greater pre- to post-surgery improvements in FACE-Q appearance and psychosocial scores than cisgender women (P<.001).
Methodological Strengths
- Objective morphometric assessments using CT imaging complemented by standardized FACE-Q patient-reported outcomes.
- At least 1-year postoperative follow-up for all included patients.
Limitations
- Retrospective, single-center design with potential selection bias.
- Modest sample size and lack of long-term (>1 year) and functional outcomes.
Future Directions: Prospective, multicenter studies with longer follow-up, standardized cephalometric protocols, and inclusion of functional outcomes (e.g., mastication, sensation) and quality-of-life metrics.
PURPOSE: Facial feminization surgery (FFS) is a group of surgical procedures for transgender or cisgender women with masculine facial characteristics. This study aimed to investigate the cosmetic outcomes of middle and lower FFS including reduction malarplasty and mandibular angle ostectomy in East Asian transgender and cisgender women. METHODS: A retrospective study was conducted using the clinical notes and records of transgender women (Group I) and cisgender women (Group II) who underwent FFS, incorporating reduction malarplasty and mandibular angle ostectomy at the West China Hospital of Stomatology, Sichuan University. Outcomes were assessed using computed tomography (CT) images, which were supplemented by medical records and photographs. Data were collected preoperatively and at intervals of at least 1 year postoperatively, focusing on mid- and lower-facial width, mandibular angle, and patient-reported complications. FACE-Q reports of facial appearance and psychosocial parameters were also compared between the 2 groups. RESULTS: Thirty-four transgender women and 39 cisgender women were enrolled in the study. Significant reductions in mid- and lower-facial width, and mandibular angle, were observed in all patients (P <.001). Transient nerve weaknesses were the primary complications noted. Group I exhibited a more pronounced improvement in FACE-Q scores pre- and postsurgery compared to Group II (P <.001). CONCLUSION: FFS using reduction malarplasty and mandibular contouring procedures is an effective technique for feminizing the facial skeleton. Remarkably, transgender women experienced a more significant enhancement in facial appearance and psychosocial well-being following FFS when compared to cisgender women.